AzTrials
AzTrials

Defibrillators, ImplantableSLEW REGISTRYNCT06842940

Slew Rate As a Predictor for Optimal Lead Fixation

An observational study of Defibrillators, Implantable and Electrodes, Implanted, run by Paolo Pastori, MD at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to identify the most reliable electrical parameter measured at the time of implantation that can predict optimal lead fixation and long-term lead performance in patients undergoing transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implant. Read more about this study

Who is it for?
Ages 18 to 100 years
How many people
516 participants
Where
1 siteItaly
Study dates
18 Feb 2023to 28 Feb 2027
How long will I take part?
12 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients admitted to the hospital with an indication for scheduled or urgent transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implantation with active lead fixation

Who may be able to join

  • Implantation of a transvenous pacemaker with active lead fixation.
  • Implantation of a transvenous implantable cardioverter-defibrillator (ICD) with active lead fixation.

Who cannot join

  • Pregnancy.
  • Age under 18 years.
  • Implantation of a subcutaneous ICD (S-ICD).
  • Implantation of a leadless pacemaker.
  • Patients requiring a new lead position with a previously implanted pacemaker or ICD

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Paolo Pastori, MD contact

+39-524-515233

ppastori@ausl.pr.it

Italy1 site, 1 recruiting
  • Azienda Unità Sanitaria Locale di Parma

    Fidenza, 43036

    Nadia Campanini, +39-521-393352, ncampanini@ausl.pr.it

    Recruiting

Other trials in Italy

About this study

Official title: Evaluating Slew Rate As a Predictor for Optimal Lead Fixation in Transvenous Cardiac Implantable Devices: a Prospective Multicenter Study

The goal of this observational study is to identify the most reliable electrical parameter measured at the time of implantation that can predict optimal lead fixation and long-term lead performance in patients undergoing transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implant.

The main questions it aims to answer are:

  • Is there a correlation between the slew rate measured at the time of lead implantation and the sensing measured at the 12-month follow-up?
  • Is there a correlation between all electrical parameters recorded at implantation (including slew rate, current of injury, acute sensing, acute impedance, and acute pacing threshold) and the electrical parameters assessed at 12 months post-implantation (specifically chronic sensing, chronic impedance, and chronic pacing threshold)? Participants will undergo regular follow-up evaluations, with device interrogation visits scheduled at 1 and 12 months post-implantation as part of routine clinical care.
Read the detailed description

During the implantation of transvenous pacemakers and implantable cardiac defibrillators, the placement of active fixation leads requires the measurement of standard electrical parameters (sensing, impedance, and capture threshold) to identify the optimal pacing site before helix deployment into the cardiac muscle. Selecting the optimal site at the time of implantation is crucial to ensure long-term lead performance and to prevente potential device malfunctions secondary to threshold elevation or sensing reduction.

Two additional electrical parameters-slew rate and the current of injury-may aid in selecting the optimal pacing site. However, these parameters have been poorly studied in the literature and exhibit significant differences. While the slew rate is easily measurable, as it is automatically determined by the pacing system analyzer (PSA), the current of injury requires non-standardized, complex, operator-dependent, and time-consuming manual measurements. Additionally, the slew rate can be assessed before helix deployment, whereas the current of injury can only be measured after helix fixation. While the current of injury generally indicates adequate helix fixation, at least in the acute setting, the significance of slew rate in predicting long-term lead stability remains uncertain.

The study hypothesis is that the slew rate significantly correlates with sensed electrical activity at 12 months post-implantation and may therefore serve as a predictor of optimal long-term lead fixation and performance.

This is a prospective, observational, single-arm, investigator-initiated, multicenter, non-profit cohort study. Four Italian centers are participating: Ospedale di Fidenza, Arcispedale Santa Maria Nuova di Reggio Emilia, Ospedale Civile di Piacenza, and Azienda Ospedaliero-Universitaria di Ferrara.

Patients undergoing pacemaker or ICD implantation with active-fixation atrial or ventricular leads, either for pacing or defibrillation, will be enrolled. The lead fixation site (right ventricular apex or septum) and pacing modality (traditional right ventricular pacing or conduction system pacing) will be determined at the physician's discretion.

Electrical parameters at implantation-including slew rate, current of injury, sensing, impedance, and capture threshold-will be measured in all participating centers using the same pacing system analyzer (PSA) model (Medtronic, Model 2290). Slew rate, sensing, impedance, and capture threshold will be assessed before and after helix deployment, as well as after lead fixation.

The current of injury is defined as an increase in ST-segment elevation of at least 5 mV for ventricular leads and 1 mV for atrial leads compared to baseline in the intracardiac electrogram (EGM).

All characteristics of the current of injury-including total intracardiac EGM duration, maximum ST elevation, and maximum ST elevation 80 msec after the first EGM deflection-will be assessed immediately after helix deployment, as the current of injury is a dynamic and time-dependent electrical phenomenon.

Following implantation-after device connection and prior to discharge-and throughout the follow-up period, electrical parameters (sensing, impedance, and capture threshold) will be assessed using the device programmer provided by the manufacturer of the implanted device.

Follow-up visits are scheduled at 1 and 12 months post-implantation and may be conducted either as in-person ambulatory visits or via remote monitoring, according to the standard clinical practice of each center. During these visits, lead dislodgement and any significant variations in electrical parameters will also be assessed. The total follow-up duration is 12 months from implantation.

Keywords
pacemaker, implantable cardiac defibrillator, lead, slew rate, sensing, active fixation, electrical performance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06842940
Study groupRoleWhat they receive
All patientsPatients undergoing a transvenous cardiac devices implant with active lead fixation (pacing or defibrillator leads)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Slew rate value of active fixation leads (pacing or defibrillator leads) measured at the time of implantation

    The slew rate value of active fixation leads (pacing or defibrillator leads) measured at the time of implantation will be automatically measured in millivolts (mV) using a Medtronic pacing system analyzer (PSA) (Model 2290) prior to helix deployment for active lead fixation. Both pacemaker and implantable cardioverter-defibrillator (ICD) leads will be included in the study. The lead fixation site (right ventricular apex or septum) and the implantation approach (traditional pacing or conduction system pacing) will be determined at the physician's discretion.

    Measured: After the enrollment, at the time of implantation, prior to helix deployment for active lead fixation

Secondary outcomes (4)
  1. Current of injury of active fixation leads (pacing or defibrillator leads) measured at the time of implantation

    Characteristics of the current of injury-including total intracardiac EGM duration (msec), maximum ST elevation (mm), and maximum ST elevation 80 msec after the first EGM deflection (mm)-will be manually measured using the Medtronic PSA Model 2290 immediately after helix deployment during implantation

    Measured: After the enrollment, at the time of implantation, immediately following helix deployment for active lead fixation

  2. Sensing of active fixation leads (pacing or defibrillator leads)

    Sensing (mV) will be automatically measured using the PSA 2290 before and after helix deployment, as well as after lead fixation, followed by assessment via the device programmer at the end of the implant procedure and prior to discharge.

    During scheduled device interrogation visits at 1 and 12 months post-implant, sensing will be evaluated automatically using the device programmer.

    Measured: From enrollment at the time of implantation to the end of follow-up at 12 months

  3. Capture threshold of active fixation leads (pacing or defibrillator leads)

    Capture threshold (volts with a fixed impulse duration of 0.4 msec) will be manually measured using the PSA 2290 before and after helix deployment, as well as after lead fixation. This will be followed by assessment via the device programmer at the end of the implant procedure and prior to discharge.

    During scheduled device interrogation visits at 1 and 12 months post-implant, capture threshold will be manually evaluated using the device programmer.

    Measured: From enrollment at the time of implantation to the end of follow-up at 12 months

  4. Impedance of active fixation leads (pacing or defibrillator leads)

    Impedance (ohm) will be automatically measured using the PSA 2290 before and after helix deployment, as well as after lead fixation, followed by assessment via the device programmer at the end of the implant procedure and prior to discharge.

    During scheduled device interrogation visits at 1 and 12 months post-implant, impedance will be evaluated automatically using the device programmer.

    Measured: From enrollment at the time of implantation to the end of follow-up at 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Feb 2025
  2. Study start18 Feb 2023
  3. Primary completion28 Feb 2026 (estimated)
  4. Study completion28 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
516 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06842940
Sponsor's protocol ID
920/2021/OSS/AUSLPR
Acronym
SLEW REGISTRY
Status last verified
Feb 2025
First submitted
14 Feb 2025
Last updated
24 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Defibrillators, Implantable and Electrodes, Implanted, run by Paolo Pastori, MD at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Paolo Pastori, MD (+39-524-515233, ppastori@ausl.pr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Slew rate value of active fixation leads (pacing or defibrillator leads) measured at the time of implantation (time frame: After the enrollment, at the time of implantation, prior to helix deployment for active lead fixation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in